QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 6-stocks-goldman-sachs-says-are-poised-for-potential-acquisition-in-next-12-months--including-a-huge-200-winner

Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year.

 jp-morgan-maintains-overweight-on-vera-therapeutics-lowers-price-target-to-53

JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:VERA) with a Overweight and lowers the price target from $...

 vera-therapeutics-files-for-offering-of-up-to-200m-class-a-common-stock

- SEC Filing

 vera-therapeutics-q2-2025-eps-120-misses-083-estimate-vera-reported-5568m-in-cash-cash-equivalents-and-marketable-securities

Vera expects cash position to be sufficient to fund operations through potential approval and us commercial launch of Atacicept...

 wolfe-research-downgrades-vera-therapeutics-to-peer-perform

Wolfe Research analyst Andy Chen downgrades Vera Therapeutics (NASDAQ:VERA) from Outperform to Peer Perform.

 vera-therapeutics-secures-500m-credit-facility-with-lower-rates-boosting-financial-flexibility

Vera Therapeutics, Inc. ("Vera"), a late clinical-stage biotechnology company focused on developing and commercializing...

 scotiabank-maintains-sector-outperform-on-vera-therapeutics-raises-price-target-to-65

Scotiabank analyst Greg Harrison maintains Vera Therapeutics (NASDAQ:VERA) with a Sector Outperform and raises the price tar...

 kidney-health-focused-vera-therapeutics-stock-price-spikes-on-heels-of-successful-trial-data

Vera Therapeutics' share price surged over 65% during the pre-market trading session after the company released ORIGIN Phas...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION